First Week of CLDX August 2026 Options Trading

Celldex Therapeutics (CLDX) is presented with two option trade ideas: a $25 put bid at $3.90 which would set an effective purchase basis of $21.10 versus the current stock price of $26.53 (put is ~6% OTM) and carries a 66% modeled probability of expiring worthless, implying a 15.60% return (23.53% annualized) on cash commitment. On the call side, a $34 covered call can be sold for a $2.00 bid (≈28% premium to current price) offering a 35.70% total return if called by August 2026, with a 57% chance of expiring worthless and a 7.54% yield boost (11.37% annualized). Implied volatilities are elevated (put 76%, call 68%) versus a 12‑month trailing volatility of 58%, indicating option-rich opportunities for income-seeking or yield-enhancing strategies but also higher underlying volatility risk.

Analysis

Market structure: The option chain (Aug 2026 $25 put bid $3.90; $34 call bid $2.00) benefits option premium sellers, market-makers collecting theta, and buyers seeking synthetic entry at lower cost; it penalizes pure long-only retail that must absorb binary biotech risk. A 76% put IV vs 68% call IV and 58% realized vol reveals a pronounced downside skew — demand for protection > upside speculation — which supports continued rich bid for puts and elevated hedging flows that can amplify intraday moves into clinical catalysts.

Risk assessment: Tail risks are clinical readout failure, sudden dilutive financing, or an FDA rejection that could halve market cap — a >50% downside is plausible for small-cap biotechs and not priced out despite put IV premium. Timeframes: immediate (days) volatility spikes around press releases, short-term (weeks–months) potential assignment or roll decisions, long-term (quarters) company funding/dilution trajectory. Hidden dependencies include company cash runway and milestone timing; a financing announced within 60–120 days would force reconsideration of any assignment plan.

Trade implications: For capital-efficient exposure, cash‑secured sale of Aug 2026 $25 puts (net effective cost basis $21.10) yields 15.6% one‑time or 23.5% annualized; prefer selling them with size limits (2–3% portfolio) or converting to a 25/20 put credit spread to cap tail. If already long, sell Aug 2026 $34 covered calls to lock 35.7% upside while collecting 7.54% yield boost; close or roll if stock >$32.50 or IV compresses below 50. Consider pair trades: long CLDX synthetically (put sell) vs short a small‑cap biotech ETF (IBB alternative) to neutralize sector beta.

Contrarian angles: Consensus focuses on income via premium but underestimates binary upside — a positive Phase/data/FDA sequence could send CLDX >>$34, making covered calls expensive in opportunity cost terms. Conversely, the market may be underpricing the probability of dilutive financings; naked put sellers should assume assignment and plan capital or use credit spreads. Historical parallels (small‑cap biotech with elevated put skew) show rapid IV collapse post‑catalyst; volatility sellers must be prepared for large realized moves and execution risk.

Key Decisions for Investors

• Establish a 2–3% portfolio allocation via selling Aug 2026 CLDX $25 cash‑secured puts at or above $3.90 (net post-premium cost basis $21.10). Only execute if you can hold assignment; set a hard capital reserve and cap position size so max cash commitment ≤3% of NAV.
• If already long CLDX (or plan to own), sell Aug 2026 $34 covered calls for $2.00 to capture a 7.54% yield boost and 35.7% capped upside; plan to close or roll if stock trades >$32.50 or IV falls below 50 within 30 trading days.
• Prefer defined‑risk option structures: if uncomfortable with naked puts, sell 25/20 put credit spreads (receive ~1.80–2.20 depending on fills) to limit tail loss and allocate the freed capital to a short small‑cap biotech index ETF position (size 50–75% of CLDX notional) to hedge sector risk.
• Monitor three binary catalysts over the next 60–120 days—trial readouts, cash runway filings, and any SEC shelf/secondary registration—and reduce net exposure by 50% within 3 trading days of a financing announcement or adverse readout.